

## Financial Tear Sheet

### CORPORATE PROFILE

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis' development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right drug to the right patient at the right time – represents the future of cancer therapy.

We have one marketed product, Rubraca®(rucaparib). For information on our marketed product, [click here](#).

Our lead product candidate under active development is [rucaparib](#), an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) 1, 2 and 3. Rucaparib is in advanced clinical development for the treatment of ovarian cancer and we are initiating clinical development for the treatment of metastatic castration-resistant prostate cancer patients. We maintain global rights to rucaparib.

In addition, we have two other product candidates: rociletinib; an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR), for which we have terminated enrollment in all ongoing sponsored clinical studies, though we continue to provide drug to patients whose clinicians recommend continuing rociletinib therapy. We are continuing analyses of rociletinib data to determine whether certain populations of patients may represent an opportunity for a partner committed to investing in further clinical development. Lucitanib; an oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3). Lucitanib was previously evaluated in breast and lung cancers. Development in those indications has ceased and we continue to provide drug to patients whose clinicians recommend continuing lucitanib therapy. Along with our development partner, Les Laboratoires Servier (Servier), we are continuing to evaluate development options for lucitanib.

We maintain global rights to rociletinib and exclusive development and commercial rights to lucitanib on a global basis, excluding China. Lucitanib rights to markets outside of the U.S. and Japan have been sublicensed to Servier.

### PRIMARY IR CONTACTS

Breanna Burkart

Phone: 303.625.5023

E-mail:

[bburkart@clovisoncology.com](mailto:bburkart@clovisoncology.com)

Anna Sussman

Phone: 303.625.5022

E-mail:

[asussman@clovisoncology.com](mailto:asussman@clovisoncology.com)

### STOCK PERFORMANCE

#### CLVS (Common Stock)

Exchange NASDAQ GS (US Dollar)

Price \$78.56

Change (%) ▲ 1.61 (2.09%)

Volume 1,906,898

52 Week Low \$25.50

Market Cap \$3,839,962,050

Rolling EPS -8.77

PE Ratio N/A

Shares Outstanding 48,879,354

Data as of 09/22/17 4:00 p.m. ET



## RECENT HEADLINES & EVENTS

---

09/13/17  
Clovis Oncology's Rucaparib ARIEL3 Study Data Published in The Lancet

There are currently no events scheduled.

09/07/17  
Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017

08/30/17  
Clovis Oncology to Present Comprehensive Dataset from Successful ARIEL3 Clinical Trial Program at 2017 ESMO Congress

## SEC FILINGS

---

Filing Date	Form
09/18/17	4
09/01/17	4/A
09/01/17	4/A
08/29/17	4

Powered By **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed